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Background:  Improved risk stratification using biomarkers in patients with aortic stenosis (AS) could aid clinical decisions about when, 
how, and whether to perform aortic valve replacement (AVR). In heart failure populations without AS, the prognostic utility of multiple 
biomarkers in addition to clinical factors has been demonstrated, but the utility of this approach in patients with AS is unknown.
methods:  From a prospective registry of patients with AS, 349 participants who were referred for and treated with AVR (transcatheter 
[n=187] or surgical [n=162]) were included in this analysis. Eight biomarkers of cardiovascular stress were measured on blood samples 
obtained prior to AVR: growth differentiation factor 15 (GDF15), soluble ST2 (sST2), galectin-3, amino-terminal pro-B-type natriuretic 
peptide (NTproBNP), high sensitivity cardiac troponin T, myeloperoxidase (MPO), high sensitivity C-reactive protein, and monocyte 
chemotactic protein-1. Mean f/u was 1.6±1.1 years; 72 patients died. A multimarker score was developed using a Cox proportional hazards 
model for all-cause mortality and ROC-determined biomarker cut-points.
results:  Four biomarkers (GDF15, sST2, NTproBNP, and MPO) were retained in the model and low (n=112), medium (n=128), and high 
(n=109) scores defined. After adjustment for the Society of Thoracic Surgeons (STS) risk score, a high multimarker score compared to a 
low score was associated with increased mortality (adjusted HR 5.61, 95% CI 2.45-12.88). Among those at intermediate or high surgical 
risk with an STS score ≥4, those with a high multimarker score had a 1-year mortality of 35%, whereas in those with a low multimarker 
score it was 4%. When added to the STS score, the multimarker score significantly improved the 1-year survival c-statistic (p=0.024), 
integrated discrimination index (p<0.001) and provided a category-free net reclassification improvement of 66% at 1 year (p<0.001).
conclusion:  These findings demonstrate the potential utility of multiple biomarkers reflecting diverse pathways to aid in risk stratification of 
patients with AS. Further studies are needed to evaluate their utility in clinical decision making in specific AS populations.
